Prediction of Effect of Pegylated Interferon Alpha-2b plus Ribavirin Combination Therapy in Patients with Chronic Hepatitis C Infection
Treatment with pegylated interferon alpha-2b (PEGIFN) plus ribavirin (RBV) is standard therapy for patients with chronic hepatitis C. Although the effectiveness, patients with high titres of group Ib hepatitis C virus (HCV) respond poorly compared to other genotypes. At present, we cannot predict th...
Main Authors: | , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229481/ |